PT  - JOURNAL ARTICLE
AU  - Yueguo Li
AU  - Ning Zhang
TI  - Association between HER-2 Over-Expression and Prognosis in Human Osteosarcoma: a Meta-Analysis
AID  - 10.1007/s11805-008-0367-x
DP  - 2008 Oct 01
TA  - Chinese Journal of Clinical Oncology
PG  - 367--372
VI  - 5
IP  - 5
4099  - http://www.cancerbiomed.org/content/5/5/367.short
4100  - http://www.cancerbiomed.org/content/5/5/367.full
SO  - Cancer Biol Med2008 Oct 01; 5
AB  - OBJECTIVE Various studies examining the relationship between HER-2 over-expression and the response to chemotherapy and clinical outcome in patients with osteosarcoma have yielded inconclusive results. The purpose of the current study was to evaluate the relation of HER-2 status with the response to chemotherapy and clinical outcome in osteosarcoma.METHODS We conducted a meta-analysis of 6 studies that evaluated the correlation between HER-2 status and histologic response to chemotherapy and 2-year survival. Data were synthesized in summary receiver operating characteristic curves and with summary likelihood ratios (LRs) and relative risk.RESULTS The quantitative synthesis showed that HER-2 status is not a prognostic factor for the response to chemotherapy. The positive LR was 1.27 (95% confidence interval, 0.91~1.77), and the negative LR was 0.68 (95% confidence interval, 0.38~1.22). There was no significant between-study heterogeneity. HER2-positive status tended to be associated with a worse 2-year survival, but the overall results were not formally statistically significant.CONCLUSION HER-2 status is not associated with the histologic response to chemotherapy in patients with osteosarcoma, whereas HER-2 positive patients may be associated with decreased survival.